Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2009
Business Overview: Bio-Rad is a multinational manufacturer and distributor of Life Science research and Clinical Diagnostics products. The company operates two primary segments: Life Science and Clinical Diagnostics. Approximately 66% of sales are generated internationally, exposing the company to foreign currency fluctuations.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2009 |
Six Months Ended June 30, 2009 |
|---|---|---|
| Net Sales | $427.2 | $828.1 |
| Gross Profit | $242.0 | $470.9 |
| Gross Margin | 56.6% | 56.9% |
| Operating Income | $55.9 | $107.3 |
| Net Income (Attributable to Bio-Rad) | $38.0 | $68.2 |
| Diluted EPS | $1.37 | $2.47 |
| Cash and Cash Equivalents | $533.5 (Balance Sheet) | N/A |
| Operating Cash Flow | N/A | $111.9 |
| Total Debt | $744.1 (Long-term + Current) | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 5.6% in Q2 2009 and 5.3% in the first half of 2009 compared to the prior year. However, on a currency-neutral basis, sales increased 3.5% in Q2 and 3.4% for the six-month period.
- Margin Expansion: Consolidated gross margins improved to 56.6% in Q2 (from 54.9% in 2008) and 56.9% for the six months (from 54.3% in 2008). Improvements were driven by better factory overhead absorption, cost reductions, and the cessation of certain royalties in the Clinical Diagnostics segment.
- Increased Leverage: Total debt increased significantly to $744.1 million from $453.2 million at year-end 2008. This was primarily due to the issuance of $300 million in 8.0% Senior Subordinated Notes in May 2009.
- Interest Expense: Interest expense rose 29.6% in Q2 and 14% for the six months ended June 30, 2009, reflecting the new debt issuance.
- Cash Position: Cash and cash equivalents grew from $204.5 million at December 31, 2008, to $533.5 million at June 30, 2009, bolstered by the debt proceeds and strong operating cash flow.
Guidance, Outlook, and Risks
Management Commentary:
- Market Conditions: The market for reagents remains good, though growth has slowed due to measured public and private grant funding. Large capital equipment sales have slowed as biotechnology customers face capital constraints.
- Segment Performance: The Life Science segment faced headwinds from weakened European sales and NIH/NSF spending delays. The Clinical Diagnostics segment showed growth in quality control, microbiology, and blood virus testing, aided by the BioPlex 2200 system placements.
- Acquisitions: The company acquired remaining noncontrolling interests in DiaMed Holding AG for approximately $30 million in April 2009. Management continues to evaluate potential acquisitions.
Risks and Contingencies:
- Economic Environment: Global recession, tighter credit conditions, and volatile oil prices may adversely affect customer spending and liquidity.
- Currency Risk: A strengthening U.S. dollar negatively impacts reported international sales, though it may lower costs for international manufacturing.
- Debt Covenants: The company must comply with leverage, interest coverage, and net worth tests under its credit agreements and indentures. Breach could result in default.
- Government Funding: Dependence on government grants for research and healthcare reform policies poses uncertainty for future demand.
Unusual Items:
- Tax Relief: Other income included a one-time $4.6 million benefit from the relief of a foreign non-income based tax obligation.
- Investment Impairments: The company recognized impairments on certain available-for-sale investments but does not consider the remaining unrealized losses to be other-than-temporary.
Investor Verification Checklist
- Debt Servicing: Verify the company's ability to service the new $300 million debt issuance and maintain compliance with leverage covenants given the economic downturn.
- Currency Impact: Assess the sensitivity of future earnings to U.S. dollar strength, as 66% of sales are international.
- Capital Spending Trends: Monitor the recovery of large capital equipment sales in the Life Science segment, which has been delayed by customer budget constraints.
- Acquisition Integration: Review the final purchase price allocation for the DiaMed distributor acquisitions and the integration progress of the BioPlex 2200 system.
- Investment Portfolio: Confirm the status of available-for-sale investments with unrealized losses to ensure no further other-than-temporary impairment charges are required.